康希諾-B(06185.HK)首批吸入用新冠疫苗運抵摩洛哥
康希諾生物-B(06185.HK)宣布,旗下首批吸入用重組新冠病毒疫苗(5型腺病毒載體)「克威莎霧優」日前已運抵摩洛哥,令摩洛哥成為首個推廣克威莎霧優的海外國家,為支持和加速建立大規模的免疫保護提供創新解決方案,該批次吸入用疫苗將作為加強針使用。
克威莎霧優是全球首款被用於「序貫加強免疫」的吸入用新冠疫苗,今年9月開始在中國進行廣泛推廣,作為加強針使用,11月於摩洛哥獲得緊急使用許可,是康希諾吸入用新冠疫苗首次於海外獲批。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.